TLSI — TriSalus Life Sciences, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1826667 ·
Last close
$3.77
Market Cap
$231.54M
52W High
$4.85
52W Low
$2.20
ADV30
605,240
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,899,000 | 7,669,000 | -8,411,000 | 1,539,000 | 70,979,000 | 56,553,000 | 58,172,000 |
| Dec 2025 | 13,205,000 | 11,443,000 | -3,271,000 | -9,753,000 | 35,331,000 | 20,439,000 | 69,192,000 |
| Sep 2025 | 11,566,000 | 9,660,000 | -9,014,000 | -10,811,000 | 36,463,000 | 22,687,000 | 63,188,000 |
| Jun 2025 | 11,213,000 | 9,411,000 | -7,332,000 | -8,288,000 | 41,317,000 | 26,490,000 | 60,740,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,993,000
Investing CF
$-265,000
Financing CF
$63,461,000
CapEx
$-1,152,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-329,044,000
Inventory
$3,778,000
Receivables
$5,215,000
ST Investments
—
EBIT TTM
$-21,536,000
Pretax Income TTM
$-27,307,000
Interest Exp TTM
$5,771,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$44,883,000
EBITDA
$-27,439,000
Free Cash Flow
$-9,303,375
Enterprise Value
$209,474,336
Total Cash
$56,553,000
Total Debt
$34,487,000
Shares Out
61,416,535
Trailing EPS
$-1.42
Book Value
$0.21
ROE
—
ROA
-35.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 45,151,000 | -26,946,000 | -39,227,000 | 35,331,000 | 69,192,000 | — | -18,012,000 |
| Dec 2024 | 29,431,000 | -36,165,000 | -30,045,000 | 23,971,000 | 49,865,000 | — | -40,843,000 |
| Dec 2023 | 18,511,000 | -54,475,000 | -59,363,000 | 24,598,000 | 51,663,000 | — | -50,578,000 |
| Dec 2022 | 12,398,000 | -36,439,000 | -47,187,000 | 21,995,000 | 198,325,000 | — | -32,313,000 |
TTM Snapshot
Revenues TTM
$16,480,000
NetIncome TTM
$-13,850,000
OpCashFlow TTM
$0
Assets (Latest)
$23,971,000
Forward EPS
$-0.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PROF | Profound Medical Corp. | $240.74M | $6.62 | — |
| OBIO | Orchestra BioMed Holdings, Inc. | $245.51M | $4.10 | — |
| UTMD | UTAH MEDICAL PRODUCTS INC | $216.00M | $67.84 | — |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $263.38M | $4.06 | — |
| PDEX | PRO DEX INC | $198.59M | $62.20 | — |
News headlines (Yahoo Finance, 1h cache)
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
2026-06-10 12:00 · Yahoo
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
2026-05-13 05:01 · Yahoo
TriSalus Life Sciences Q1 Earnings Call Highlights
2026-05-13 02:06 · Yahoo
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary
2026-05-13 00:47 · Yahoo
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:15 · Yahoo
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
2026-05-12 20:01 · Yahoo
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
2026-05-12 12:00 · Yahoo
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
2026-05-10 04:01 · Yahoo
VAREX IMAGING (VREX) Q2 Earnings and Revenues Miss Estimates
2026-05-07 23:05 · Yahoo
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
2026-05-04 21:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.